{"nct_id":"NCT06892522","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-06-30","start_date_type":"ACTUAL","primary_completion_date":"2036-02","primary_completion_date_type":"ESTIMATED","completion_date":"2036-03","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["ABBV"]}